Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$8.12 – $14.21
10% from low
Exchange
OTC Link
ADRC
Borrow rate
24.10%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $178.80B | $185.01B | $199.73B | $205.13B | $206.60B | $221.99B | $225.42B | $249.28B |
| Cost of revenue | $95.14B | $98.05B | $99.68B | $98.40B | $103.34B | $110.64B | $108.27B | $124.17B |
| Gross profit | $83.66B | $86.95B | $100.05B | $106.73B | $103.27B | $111.35B | $117.16B | $125.11B |
| Gross margin | 46.8% | 47.0% | 50.1% | 52.0% | 50.0% | 50.2% | 52.0% | 50.2% |
| R&D | $7.24B | $6.73B | $6.36B | $5.71B | $6.20B | $7.00B | $44.8M | $7.90B |
| Operating income | $15.04B | $15.50B | $27.10B | $30.99B | $21.12B | $19.59B | $20.71B | $19.92B |
| EBITDA | $19.22B | $17.73B | $31.64B | $34.48B | $24.91B | $23.45B | $25.90B | $26.09B |
| Net income | $11.19B | $9.85B | $18.24B | $23.43B | $17.11B | $17.03B | $14.10B | $15.39B |
| Net margin | 6.3% | 5.3% | 9.1% | 11.4% | 8.3% | 7.7% | 6.3% | 6.2% |
| EPS (diluted) | 33.30 | 57.86 | 53.56 | 69.13 | 50.82 | 50.61 | 42.44 | 47.14 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $230.9B | $96.20 | $94.56–$100.55 | 1 |
| 2028 | $240.5B | $105.82 | $104.02–$110.61 | 1 |
Forward consensus · source: Financial Modeling Prep
NIHON KOHDEN UNSP/ADR
No one on the platform currently holds NHNKY.
No tracked institution reports a position in NHNKY as of their last filing.
| Execution date | Ratio |
|---|---|
| 2015-04-02 | 2-for-1 |
No one on the platform has traded NHNKY yet.
| $3.8B |
| — |
| BUHPFBumrungrad Hospital Public Company Limited | $5.45 | +0.00% | $4.3B | — |
| CZMWFCarl Zeiss Meditec AG | $30.00 | +0.00% | $2.6B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.2× earnings vs its 0.3× historical median P/E.
Fair value ≈ $11.01 · price $8.76 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.